乳癌の小線源療法、乳房切除多い

May 08 [Tue], 2012, 11:00
文献:Smith GL et al.Association Between Treatment With Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival Among Older Women With Invasive Breast Cancer.JAMA. 2012;307(17):1827-1837.

 67歳以上の浸潤性乳癌患者9万2735人を対象に、小線源療法と全乳房照射(WBI)の治療効果を後ろ向きコホート研究で比較。5年後の乳房切除率は小線源療法群で3.95%、WBI群で2.18%(多変量調整後ハザード比2.19)だった。術後合併症は小線源療法群で多く、5年生存率は小線源療法群、WBI群で同等だった。
Original Contribution
JAMA. 2012;307(17):1827-1837. doi: 10.1001/jama.2012.3481
Association Between Treatment With Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival Among Older Women With Invasive Breast Cancer

Grace L. Smith, MD, PhD, MPH; Ying Xu, MD, MS; Thomas A. Buchholz, MD; Sharon H. Giordano, MD, MPH; Jing Jiang, MS; Ya-Chen Tina Shih, PhD; Benjamin D. Smith, MD
[+] Author Affiliations
Author Affiliations: Divisions of Radiation Oncology (Drs G. L. Smith, Buchholz, and B. D. Smith), Quantitative Sciences (Dr Xu and Jiang), and Cancer Medicine (Dr Giordano), University of Texas MD Anderson Cancer Center, Houston, Texas; and Center for Health and the Social Sciences, University of Chicago, Chicago, Illinois (Dr Shih).
ABSTRACT

Context Brachytherapy is a radiation treatment that uses an implanted radioactive source. In recent years, use of breast brachytherapy after lumpectomy for early breast cancer has increased substantially despite a lack of randomized trial data comparing its effectiveness with standard whole-breast irradiation (WBI). Because results of long-term randomized trials will not be reported for years, detailed analysis of clinical outcomes in a nonrandomized setting is warranted.

Objective To compare the likelihood of breast preservation, complications, and survival for brachytherapy vs WBI among a nationwide cohort of older women with breast cancer with fee-for-service Medicare.

Design Retrospective population-based cohort study of 92 735 women aged 67 years or older with incident invasive breast cancer, diagnosed between 2003 and 2007 and followed up through 2008. After lumpectomy 6952 patients were treated with brachytherapy vs 85 783 with WBI.

Main Outcome Measures Cumulative incidence and adjusted risk of subsequent mastectomy (an indicator of failure to preserve the breast) and death were compared using the log-rank test and proportional hazards models. Odds of postoperative infectious and noninfectious complications within 1 year were compared using the χ2 test and logistic models. Cumulative incidences of long-term complications were compared using the log-rank test.

Results Five-year incidence of subsequent mastectomy was higher in women treated with brachytherapy (3.95%; 95% CI, 3.19%-4.88%) vs WBI (2.18%; 95% CI, 2.04%-2.33%; P < .001) and persisted after multivariate adjustment (hazard ratio [HR], 2.19; 95% CI, 1.84-2.61, P < .001). Brachytherapy was associated with more frequent infectious (16.20%; 95% CI, 15.34%-17.08% vs 10.33%; 95% CI, 10.13%-10.53%; P < .001; adjusted odds ratio [OR], 1.76; 1.64-1.88) and noninfectious (16.25%; 95% CI, 15.39%-17.14% vs 9.00%; 95% CI, 8.81%-9.19%; P < .001; adjusted OR, 2.03; 95% CI, 1.89-2.17) postoperative complications; and higher 5-year incidence of breast pain (14.55%, 95% CI, 13.39%-15.80% vs 11.92%; 95% CI, 11.63%-12.21%), fat necrosis (8.26%; 95% CI, 7.27-9.38 vs 4.05%; 95% CI, 3.87%-4.24%), and rib fracture (4.53%; 95% CI, 3.63%-5.64% vs 3.62%; 95% CI, 3.44%-3.82%; P ≤ .01 for all). Five-year overall survival was 87.66% (95% CI, 85.94%-89.18%) in patients treated with brachytherapy vs 87.04% (95% CI, 86.69%-87.39%) in patients treated with WBI (adjusted HR, 0.94; 95% CI, 0.84-1.05; P = .26).

Conclusion In a cohort of older women with breast cancer, treatment with brachytherapy compared with WBI was associated worse with long-term breast preservation and increased complications but no difference in survival.
  • URL:https://yaplog.jp/cagealapins/archive/40
Comment
小文字 太字 斜体 下線 取り消し線 左寄せ 中央揃え 右寄せ テキストカラー 絵文字 プレビューON/OFF

不正な自動コメント投稿を防ぐため、チェックボックスにチェックをしてください。

利用規約に同意
 X 
禁止事項とご注意
※本名・メールアドレス・住所・電話番号など、個人が特定できる情報の入力は行わないでください。
「ヤプログ!利用規約 第9条 禁止事項」に該当するコメントは禁止します。
「ヤプログ!利用規約」に同意の上、コメントを送信してください。